RISK WARNING: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
RISK WARNING: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trusted Trading Platform
Free account
Worldwide Trading
Portfolio Management
genmab

Genmab  

nasdaq copenhagen

Genmab A/S (GMABxcse) is a Danish biotechnology company headquartered in Copenhagen. The company specializes in the creation and development of differentiated antibody therapeutics for cancer and other serious diseases. Its key product, Darzalex (daratumumab), developed in partnership with Johnson & Johnson, is a blockbuster treatment for multiple myeloma. Genmab also has a growing pipeline of bispecific antibodies and next-generation immunotherapies. It is a constituent of the OMX Copenhagen 25 (C25) index on Nasdaq Copenhagen and is also listed on Nasdaq in the US. The company is one of Europe's most valuable biotech firms.

 GMAB symbol info
 
 


 
Top stories by TradingView
 Technical analysis for GMAB
 
GMAB chart

Start trading
genmab now

At In2Markets, we offer unique strategies designed to align with your goals and adapt to changing market conditions. Our team will provide you with real-time support and expert insights to answer your question in a quick and personal way. Whether you’re trading or managing your portfolio, we combine innovation with a personalized approach to ensure you stay ahead.

Update I2M Telefoon (1)